|
|
|
|
| Instant Update: Fri 27 January |
|
Re-subs dominate March PBAC - Numerous drugs come up for second or third time; Wholesalers scoff at Pfizer - Latest changes to direct distribution "peripheral"; Kineret granted orphan status - Re-emerges a year after PBS delisting
» full report |
|
| Watson buys Ascent in $375m deal |
|
Breaking News - Wednesday 25 January: Watson Pharmaceuticals has become Australia's fifth biggest generics company overnight through the AU$375 million acquisition of Ascent Pharmahealth
» full report |
|
| TGA boss quits to join NSW Health |
|
A high-level appointment at New South Wales Health has emerged as the
reason for the shock resignation of TGA National Manager, Rohan Hammett, just
weeks after the regulator announced its 'Blueprint' for the future
» full report |
|
| Nycomed pulls Daxas filing |
|
Nycomed's bid to get COPD treatment Daxas onto the market in
Australia has suffered a significant delay after the TGA requested the results of
further clinical trials before reconsidering it for approval
» full report |
|
| Wholesalers rocked by April cuts |
|
The size of planned PBS price cuts in April has left pharmaceutical wholesalers
reeling with Australian Pharmaceutical Industries saying they were
significantly greater than expected
» full report |
|
| Fears Pradaxa review may repeat |
|
Medicines Australia is seeking assurances from the Government that the review
of anticoagulants, prompted by the situation surrounding Boehringer
Ingelheim's Pradaxa, is "a one-off and not a new process"
» full report |
|
|
|
|
|
|
|
|
- Sandoz trumpets biosimilar hopes - Announces new phase III trial - » full report
- Bayer plans bowel cancer filing - Regorafenib success prompts next move - » full report
|
|
|
| © 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus | Design: Jolly Good Design
|
